TVAX Biomedical
TVAX Biomedical is developing an exciting novel approach to cancer treatment (TVAX Immunotherapy®) that offers the opportunity of improved clinical outcomes for patients with any type of cancer, low toxicity and the potential for fundamentally changing the way cancer is treated
TVAX Immunotherapy® is a unique, personalized T cell therapy that employs the natural ability of activated ‘killer’ T cells to attack cancer cells. This adoptive cell therapy is a two-step treatment that includes a vaccination pre-treatment, followed by activated T cell therapy to trigger the immune system to attack cancer in the body.
Treatment
TVAX’s lead candidate (TVI-Brain-1) is currently being evaluated for the treatment of brain cancer, specifically glioblastoma. The United States Food and Drug Administration (FDA) granted the company Fast Track Designation for its pivotal Phase 2b trial for TVI-Brain-1, which is designed to support the therapy’s potential FDA approval. Additionally, the company received a $2 million grant from the FDA office of orphan products for this clinical trial.